search
Back to results

Assessment of Intracerebral Hematoma

Primary Purpose

Intracerebral Hematoma

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
transcranial duplex sonography
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Intracerebral Hematoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. first ever non traumatic supratentorial primary intracerebral haemorrhage on non contrast CT brain
  2. admitted within 24 hours of symptom onset

Exclusion Criteria:

  1. blood diseases, decompansated hepatic or renal impairment, or encephalopathy caused by electrolyte disturbance
  2. on anticoagulant treatment
  3. if devolped major complications during hospitalization ( e.g sever chest infection, hypoxia, or deep venous thrombosis )
  4. comorbid neurological or psychiatric disorders

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    patients assessed by transcranial duplex sonography

    Arm Description

    Outcomes

    Primary Outcome Measures

    change from baseline in volume of intracerebral hematoma

    Secondary Outcome Measures

    Full Information

    First Posted
    December 3, 2021
    Last Updated
    December 3, 2021
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05158660
    Brief Title
    Assessment of Intracerebral Hematoma
    Official Title
    Assessment of Intracerebral Hematoma Using Transcranial Duplex _ Hospital Based Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2021
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2022 (Anticipated)
    Primary Completion Date
    October 2022 (Anticipated)
    Study Completion Date
    January 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The study will assess acute intracerebral hematoma expansion within the first 48 hours from the onset using transcranial duplex sonography in patients who have acute intracerebral hematoma , and will also assess the correlation between the transcranial duplex sonography measurements and the clinical outcome of these patients .

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Intracerebral Hematoma

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    patients assessed by transcranial duplex sonography
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    transcranial duplex sonography
    Intervention Description
    it is an imaging device that will measure the intracerebral hematoma expansion
    Primary Outcome Measure Information:
    Title
    change from baseline in volume of intracerebral hematoma
    Time Frame
    at baseline, then 24 hour after the baseline, and finally 48 hours after the baseline

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: first ever non traumatic supratentorial primary intracerebral haemorrhage on non contrast CT brain admitted within 24 hours of symptom onset Exclusion Criteria: blood diseases, decompansated hepatic or renal impairment, or encephalopathy caused by electrolyte disturbance on anticoagulant treatment if devolped major complications during hospitalization ( e.g sever chest infection, hypoxia, or deep venous thrombosis ) comorbid neurological or psychiatric disorders
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    waleed Gafar
    Phone
    00201012110708
    Email
    waleed.gafar1995@gmail.com

    12. IPD Sharing Statement

    Learn more about this trial

    Assessment of Intracerebral Hematoma

    We'll reach out to this number within 24 hrs